| Q34466861 | Advancing host-directed therapy for tuberculosis |
| Q28485323 | Application of a stochastic modeling to assess the evolution of tuberculous and non-tuberculous mycobacterial infection in patients treated with tumor necrosis factor inhibitors |
| Q41120913 | Biologics in dermatology: adverse effects |
| Q52668339 | Cytokine Biomarkers Associated with Human Extra-Pulmonary Tuberculosis Clinical Strains and Symptoms. |
| Q37156636 | Infectious complications associated with monoclonal antibodies and related small molecules |
| Q92626116 | Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events |
| Q35199257 | Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy |
| Q84229705 | Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent |
| Q38848891 | Mathematical Models of Tuberculosis Reactivation and Relapse |
| Q33939033 | Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review |
| Q35154706 | QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment |
| Q42376342 | Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials |
| Q37473648 | Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy |
| Q48891027 | Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes |
| Q38539281 | Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues |
| Q42320614 | Tuberculosis Cutis Orificialis in Adalimumab Related Immunosupressive Patient |
| Q36968737 | Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis |
| Q37298854 | Tumour necrosis factor antagonists: structure, function, and tuberculosis risks |
| Q84279863 | [Etanercept and infection - latent tuberculosis] |
| Q82719630 | [Infectious complications of biologic therapy in patients with rheumatoid arthritis] |